Department of Liver Diseases and Digestive Interventional Radiology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Military Medical Innovation Center, Fourth Military Medical University, Xi'an, China.
Hepatol Int. 2023 Oct;17(5):1192-1204. doi: 10.1007/s12072-023-10493-1. Epub 2023 May 31.
Baveno VII workshop recommends management of acute variceal bleeding (AVB) in cirrhotic patients with nonmalignant portal vein thrombosis (PVT) should be performed according to the guidelines for patients without PVT. Nevertheless, whether PVT affects the outcome of patients with cirrhosis and AVB remains unclear. The aim of this study was to assess the clinical impact of PVT on the outcomes in the pre-emptive TIPSS eligible patients with cirrhosis and AVB.
From December 2010 to June 2016, 1219 consecutive cirrhotic patients admitted due to AVB with (n = 151; 12.4%) or without PVT (n = 1068; 87.6%), who received drug plus endoscopic treatment (a combination of vasoactive drugs, antibiotics, and endoscopic ligation for AVB, followed by beta-blockers plus variceal ligation for prevention of rebleeding) were retrospectively included. Fine and Gray competing risk regression models were taken to evaluate the impact of PVT on clinical outcomes after adjusting for potential confounders.
During follow-up, 211 patients (17.3%) died, 490 (40.2%) experienced further bleeding, and 78 (6.4%) experienced new or worsening ascites within 1 year. Compared with those without PVT, patients with PVT had a similar risk of mortality (PVT vs no-PVT: 19.9% vs 16.7% at 1 year; adjusted HR 0.88, 95%CI 0.51-1.52, p = 0.653), further bleeding (47.0% vs 39.2% at 1 year, adjusted HR 1.19, 95% CI 0.92-1.53, p = 183), and new or worsening ascites (7.9% vs 9.6%, adjusted HR 0.70, 95% CI 0.39-1.28, p = 0.253) after adjusting for confounders in multivariable models. These findings were consistent across different relevant subgroups and confirmed by propensity score matching analysis.
Our study showed no evidence that the PVT was associated with an improved or worsened outcome among cirrhotic patients with AVB who received standard treatment.
Baveno VII 研讨会建议,对于伴有非恶性门静脉血栓形成(PVT)的肝硬化患者的急性静脉曲张出血(AVB)的管理,应根据无 PVT 患者的指南进行。然而,PVT 是否会影响肝硬化伴 AVB 患者的结局尚不清楚。本研究旨在评估 PVT 对肝硬化和 AVB 患者行预防性经颈静脉肝内门体分流术(TIPSS)合格患者结局的临床影响。
2010 年 12 月至 2016 年 6 月,连续纳入 1219 例因 AVB 入院的肝硬化患者,其中伴有 PVT(n=151;12.4%)或无 PVT(n=1068;87.6%),接受药物加内镜治疗(即曲张静脉出血的血管活性药物、抗生素和内镜结扎治疗,随后β受体阻滞剂加静脉曲张结扎预防再出血)。采用 Fine 和 Gray 竞争风险回归模型,在调整潜在混杂因素后,评估 PVT 对临床结局的影响。
随访期间,211 例患者(17.3%)死亡,490 例(40.2%)发生进一步出血,78 例(6.4%)在 1 年内发生新的或加重的腹水。与无 PVT 患者相比,有 PVT 的患者的死亡率风险相似(PVT 与无-PVT:1 年时分别为 19.9%和 16.7%;调整后的 HR 0.88,95%CI 0.51-1.52,p=0.653)、进一步出血(1 年时分别为 47.0%和 39.2%;调整后的 HR 1.19,95%CI 0.92-1.53,p=183)和新的或加重的腹水(7.9%和 9.6%;调整后的 HR 0.70,95%CI 0.39-1.28,p=0.253)。这些发现与多变量模型中的混杂因素调整后一致,并通过倾向评分匹配分析得到证实。
我们的研究结果表明,在接受标准治疗的肝硬化伴 AVB 患者中,PVT 与改善或恶化的结局之间没有证据表明存在关联。